SG11201810765PA - Medium chain fatty acid esters of beta-hydroxybutyrate and butanediol and compositions and methods for using same - Google Patents
Medium chain fatty acid esters of beta-hydroxybutyrate and butanediol and compositions and methods for using sameInfo
- Publication number
- SG11201810765PA SG11201810765PA SG11201810765PA SG11201810765PA SG11201810765PA SG 11201810765P A SG11201810765P A SG 11201810765PA SG 11201810765P A SG11201810765P A SG 11201810765PA SG 11201810765P A SG11201810765P A SG 11201810765PA SG 11201810765P A SG11201810765P A SG 11201810765PA
- Authority
- SG
- Singapore
- Prior art keywords
- fatty acid
- bhb
- california
- international
- acid esters
- Prior art date
Links
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 title abstract 4
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 150000002711 medium chain fatty acid esters Chemical class 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 5
- 229930195729 fatty acid Natural products 0.000 abstract 5
- 239000000194 fatty acid Substances 0.000 abstract 5
- -1 fatty acid esters Chemical class 0.000 abstract 3
- 240000005020 Acaciella glauca Species 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000002148 esters Chemical class 0.000 abstract 2
- 150000004665 fatty acids Chemical class 0.000 abstract 2
- 235000003499 redwood Nutrition 0.000 abstract 2
- WHBMMWSBFZVSSR-UHFFFAOYSA-M 3-hydroxybutyrate Chemical compound CC(O)CC([O-])=O WHBMMWSBFZVSSR-UHFFFAOYSA-M 0.000 abstract 1
- 241001263180 Auriparus flaviceps Species 0.000 abstract 1
- 235000003332 Ilex aquifolium Nutrition 0.000 abstract 1
- 241000209027 Ilex aquifolium Species 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/34—Esters of acyclic saturated polycarboxylic acids having an esterified carboxyl group bound to an acyclic carbon atom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
- A23L29/045—Organic compounds containing nitrogen as heteroatom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/003—Esters of saturated alcohols having the esterified hydroxy group bound to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
- C07C69/675—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids of saturated hydroxy-carboxylic acids
-
- G—PHYSICS
- G02—OPTICS
- G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
- G02B1/00—Optical elements characterised by the material of which they are made; Optical coatings for optical elements
- G02B1/04—Optical elements characterised by the material of which they are made; Optical coatings for optical elements made of organic materials, e.g. plastics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/54—Proteins
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Psychology (AREA)
- Physics & Mathematics (AREA)
- Diabetes (AREA)
- Mycology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Physical Education & Sports Medicine (AREA)
- General Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662346975P | 2016-06-07 | 2016-06-07 | |
| PCT/US2017/035826 WO2017213999A1 (en) | 2016-06-07 | 2017-06-02 | Medium chain fatty acid esters of beta-hydroxybutyrate and butanediol and compositions and methods for using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201810765PA true SG11201810765PA (en) | 2018-12-28 |
Family
ID=60578899
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201810765PA SG11201810765PA (en) | 2016-06-07 | 2017-06-02 | Medium chain fatty acid esters of beta-hydroxybutyrate and butanediol and compositions and methods for using same |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US10889538B2 (enExample) |
| EP (2) | EP4585270A3 (enExample) |
| JP (3) | JP7058610B2 (enExample) |
| KR (2) | KR102638807B1 (enExample) |
| CN (2) | CN114292190B (enExample) |
| AU (2) | AU2017278099B2 (enExample) |
| CA (1) | CA3026621A1 (enExample) |
| CO (1) | CO2018014167A2 (enExample) |
| IL (2) | IL263561B (enExample) |
| MX (2) | MX2021009806A (enExample) |
| RU (1) | RU2761829C2 (enExample) |
| SG (1) | SG11201810765PA (enExample) |
| WO (1) | WO2017213999A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4585270A3 (en) | 2016-06-07 | 2025-09-24 | The J. David Gladstone Institutes | Medium chain fatty acid esters of beta-hydroxybutyrate and butanediol and compositions and methods for using same |
| US11773051B2 (en) | 2017-07-21 | 2023-10-03 | Buck Institute For Research On Aging | S-enantiomers of beta-hydroxybutyrate and butanediol and methods for using same |
| US12037317B2 (en) | 2018-01-25 | 2024-07-16 | Buck Institute For Research On Aging | Synthesis of 3-hydroxybutyryl 3-hydroxybutyrate and related compounds |
| US20190248733A1 (en) * | 2018-02-14 | 2019-08-15 | Benjamin Bikman | Oral supplements of fatty acid and amino acid ketone esters to improve metabolic, physical and cognitive health |
| CN113574048B (zh) * | 2019-01-17 | 2024-06-18 | 凯托利皮克斯治疗有限责任公司 | 生产任选的酰化羟基羧酸的多元醇基酯的方法 |
| CN113508105B (zh) * | 2019-01-17 | 2025-02-28 | 凯托利皮克斯治疗有限责任公司 | 用于生产羟基羧酸脂肪醇酯的方法 |
| JP7361124B2 (ja) * | 2019-01-17 | 2023-10-13 | ケトリピックス セラポーティクス ゲーエムベーハー | キャップされた３－ヒドロキシカルボン酸およびそれらの塩およびエステルの製造方法 |
| CN110372502A (zh) * | 2019-07-25 | 2019-10-25 | 润泰化学（泰兴）有限公司 | 一种1,3-二醇的双酯化合成方法 |
| GB201918657D0 (en) | 2019-12-17 | 2020-01-29 | Tdeltas Ltd | Compounds for new use |
| JP2023543654A (ja) * | 2020-07-13 | 2023-10-18 | ケトリピックス セラポーティクス ゲーエムベーハー | 高分子カルボン酸のオキソブタノールエステルの製造方法 |
| WO2022012767A1 (de) * | 2020-07-13 | 2022-01-20 | Ioi Oleo Gmbh | Verfahren zur herstellung von polyglycerinestern von mit oxobutanol veresterten polycarbonsäuren |
| BR112023000684A2 (pt) * | 2020-07-13 | 2023-01-31 | Ioi Oleo Gmbh | Método para produzir ésteres de oxobutanol de ácidos carboxílicos poliméricos |
| CN112341542B (zh) * | 2021-01-08 | 2021-05-14 | 清华大学 | 一种3-羟基丁酰化修饰蛋白质药物及其制备方法和应用 |
| US20240122890A1 (en) * | 2021-01-26 | 2024-04-18 | Buck Institute For Research On Aging | Use of exogenous ketone esters to induce weight loss in mammals |
| US12059398B2 (en) * | 2022-08-26 | 2024-08-13 | Health Via Modern Nutrition Inc. | Compositions of 1,3-butanediol and beta-hydroxybutyric acid to provide optimal therapeutic ketosis |
| EP4483869A1 (en) | 2023-06-29 | 2025-01-01 | BOPZ nutrition Limited | Ketone esters for use in inducing ketosis in non-human mammals |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK85610C (da) | 1952-01-08 | 1958-05-27 | Unilever Nv | Fremgangsmåde til udvinding af fedstoffer af vandige sæbeopløsninger. |
| US4756907A (en) | 1978-10-17 | 1988-07-12 | Stolle Research & Development Corp. | Active/passive immunization of the internal female reproductive organs |
| US4263216A (en) * | 1978-10-20 | 1981-04-21 | The Procter & Gamble Company | Diglyceride manufacture |
| IL59407A (en) * | 1979-03-06 | 1983-12-30 | Sanofi Sa | Di-n-propylacetic acid diesters of glycerol,their preparation and pharmaceutical compositions containing them |
| US4436726A (en) * | 1980-12-15 | 1984-03-13 | Fujisawa Pharmaceutical Co., Ltd. | N-Acylpeptide compound, processes for the preparation thereof and the pharmaceutical compositions |
| US5126373A (en) | 1987-11-19 | 1992-06-30 | Henri Brunengraber | Composition for parenteral and oral nutrition |
| BE1001209A3 (fr) | 1987-11-19 | 1989-08-22 | Solvay | Compositions pharmaceutiques contenant un derive de l'acide 3-hydroxybutanoique choisi parmi les oligomeres de cet acide et les esters de cet acide ou de ces oligomeres avec du 1,3-butanediol. |
| EP0556387B1 (en) | 1988-04-27 | 1995-08-09 | Daicel Chemical Industries, Ltd. | Process for preparing optically active 1,3-butanediol |
| JP2578658B2 (ja) | 1989-02-21 | 1997-02-05 | チッソ株式会社 | 光学活性化合物及びその製造法 |
| US5008126A (en) | 1989-06-27 | 1991-04-16 | Nabisco Brands, Inc. | Long chain diol diesters as low calorie fat mimetics |
| IT1240760B (it) * | 1990-02-12 | 1993-12-17 | Sigma Tau Ind Farmaceuti | Esteri di acil-l-carnitine con l'acido gamma-idrossibutirrico e composizioni farmaceutiche che li contengono per l'inibizione della degenerazione neuronale e nel trattamento del coma. |
| EP0550779B1 (fr) | 1992-01-08 | 1995-10-18 | Societe Des Produits Nestle S.A. | Composition cosmétique ou dermatologique contenant un diol diester |
| US5536249A (en) | 1994-03-09 | 1996-07-16 | Visionary Medical Products, Inc. | Pen-type injector with a microprocessor and blood characteristic monitor |
| US6146361A (en) | 1996-09-26 | 2000-11-14 | Becton Dickinson And Company | Medication delivery pen having a 31 gauge needle |
| DE19703471A1 (de) * | 1997-01-31 | 1998-08-06 | Beiersdorf Ag | Kosmetische und dermatologische Lichtschutzformulierungen mit einem Gehalt an Triazinderivaten und Butylenglycoldiestern |
| US6323237B1 (en) | 1997-03-17 | 2001-11-27 | Btg International Limited | Therapeutic compositions |
| EP1017379B1 (en) | 1997-03-17 | 2014-12-10 | BTG International Limited | Therapeutic compositions comprising ketone bodies and precursors thereof |
| EP1027033B1 (en) * | 1997-05-14 | 2009-07-22 | The University Of British Columbia | High efficiency encapsulation of nucleic acids in lipid vesicles |
| US6197327B1 (en) | 1997-06-11 | 2001-03-06 | Umd, Inc. | Device and method for treatment of dysmenorrhea |
| US5961495A (en) | 1998-02-20 | 1999-10-05 | Becton, Dickinson And Company | Medication delivery pen having a priming mechanism |
| US6221053B1 (en) | 1998-02-20 | 2001-04-24 | Becton, Dickinson And Company | Multi-featured medication delivery pen |
| US6248095B1 (en) | 1998-02-23 | 2001-06-19 | Becton, Dickinson And Company | Low-cost medication delivery pen |
| DE60001686T2 (de) * | 1999-05-11 | 2003-08-21 | Dow Agrosciences Llc, Indianapolis | Verfahren zum Herstellen von substituierten 3-Hydroxybuttersäureester |
| US6277099B1 (en) | 1999-08-06 | 2001-08-21 | Becton, Dickinson And Company | Medication delivery pen |
| US6476079B1 (en) | 1999-12-23 | 2002-11-05 | Leiras Oy | Devices for the delivery of drugs having antiprogestinic properties |
| US20080009467A1 (en) | 2000-05-01 | 2008-01-10 | Accera, Inc. | Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimers disease and other diseases resulting from reduced neuronal metabolism |
| MXPA03003022A (es) * | 2000-10-11 | 2003-07-14 | Esperion Therapeutics Inc | Compuestos de sulfuro y disulfuro y composiciones para el control del colesterol y usos relacionados. |
| EP1528053A1 (en) | 2003-10-31 | 2005-05-04 | Lonza Ag | Process for the preparation of (S)- or (R)-4-halo-3-hydroxybutyrates |
| JP2006063001A (ja) | 2004-08-25 | 2006-03-09 | Takasago Internatl Corp | 光学活性β−ブチロラクトンの製造方法 |
| CN101326172A (zh) * | 2005-12-07 | 2008-12-17 | 思珀药品有限公司 | 茉莉酮酸酯衍生物、药物组合物及它们的使用方法 |
| CN105078773A (zh) | 2006-02-10 | 2015-11-25 | 杜邦塔特和莱尔生物产品有限责任公司 | 包括可再生基生物降解型1,3-丙二醇的生物降解型组合物 |
| AU2008206048A1 (en) * | 2007-01-18 | 2008-07-24 | Evolva Sa | Substituted 1,3-dioxanes and their uses |
| JP5054418B2 (ja) * | 2007-04-23 | 2012-10-24 | ポーラ化成工業株式会社 | クレンジング用の化粧料に好適な皮膚外用剤 |
| NO2328858T3 (enExample) | 2008-08-21 | 2018-03-10 | ||
| US8642654B2 (en) | 2009-04-16 | 2014-02-04 | Isis Innovation Limited | Hydroxybutyrate ester and medical use thereof |
| AU2009344282B2 (en) | 2009-04-16 | 2014-12-11 | Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Process for the preparation of (3R)-hydroxybutyl (3R)-hydroxybutyrate by enzymatic enantioselective reduction employing Lactobacillus brevis alcohol dehydrogenase |
| GB201002983D0 (en) | 2010-02-22 | 2010-04-07 | Tdeltas Ltd | Nutritinal composition |
| BR112012027758A2 (pt) * | 2010-04-28 | 2016-07-26 | Arkema Inc | método para melhorar estabilidade de misturas de poliol de poliuretano contendo agente de expansão de olefina halogenada |
| KR101243240B1 (ko) * | 2010-07-19 | 2013-04-04 | (주)에이씨티 | 신규 알킬디올 유도체화합물 및 이를 포함하는 미백용 피부외용제조성물 |
| CN103360243B (zh) * | 2012-03-31 | 2015-06-17 | 中国石油化工股份有限公司 | 一种1,3-二酰氧基丙烷类化合物的制备方法 |
| JP5146628B1 (ja) * | 2012-05-01 | 2013-02-20 | コニカミノルタアドバンストレイヤー株式会社 | 位相差フィルム、偏光板の製造方法および液晶表示装置 |
| KR102265842B1 (ko) | 2013-03-14 | 2021-06-15 | 옥스포드 유니버시티 이노베이션 리미티드 | (ｒ)３하이드록시부틸 (ｒ)３하이드록시부티레이트를 생산하는 방법 |
| MY180761A (en) | 2013-03-19 | 2020-12-08 | Univ South Florida | Compositions and methods for producing elevated and sustained ketosis |
| US11814664B2 (en) | 2013-05-24 | 2023-11-14 | Genomatica, Inc. | Microorganisms and methods for producing (3R)-hydroxybutyl (3R)-hydroxybutyrate |
| WO2015021128A1 (en) * | 2013-08-06 | 2015-02-12 | Imago Biosciences Inc. | Kdm1a inhibitors for the treatment of disease |
| WO2016123229A1 (en) | 2015-01-29 | 2016-08-04 | Yale University | Compositions and methods for treating nlrp3 inflammasome-related diseases and disorders |
| WO2017011294A1 (en) | 2015-07-10 | 2017-01-19 | Cognate Nutritionals, Inc. | Prophylaxis and mitigation of migraine headaches using medium chain triglycerides, ketone esters, and other ketogenic sources |
| US10245242B1 (en) | 2017-11-22 | 2019-04-02 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| EP4585270A3 (en) | 2016-06-07 | 2025-09-24 | The J. David Gladstone Institutes | Medium chain fatty acid esters of beta-hydroxybutyrate and butanediol and compositions and methods for using same |
| US11773051B2 (en) | 2017-07-21 | 2023-10-03 | Buck Institute For Research On Aging | S-enantiomers of beta-hydroxybutyrate and butanediol and methods for using same |
| US12037317B2 (en) | 2018-01-25 | 2024-07-16 | Buck Institute For Research On Aging | Synthesis of 3-hydroxybutyryl 3-hydroxybutyrate and related compounds |
| US20190262415A1 (en) | 2018-02-26 | 2019-08-29 | Ketologie LLC | Supplement for inducing and sustaining nutritional ketosis |
-
2017
- 2017-06-02 EP EP25179114.1A patent/EP4585270A3/en active Pending
- 2017-06-02 RU RU2018143895A patent/RU2761829C2/ru active
- 2017-06-02 KR KR1020227044586A patent/KR102638807B1/ko active Active
- 2017-06-02 CA CA3026621A patent/CA3026621A1/en active Pending
- 2017-06-02 MX MX2021009806A patent/MX2021009806A/es unknown
- 2017-06-02 US US16/306,524 patent/US10889538B2/en active Active
- 2017-06-02 MX MX2018015302A patent/MX385367B/es unknown
- 2017-06-02 CN CN202111675586.8A patent/CN114292190B/zh active Active
- 2017-06-02 CN CN201780041428.2A patent/CN109477993B/zh active Active
- 2017-06-02 AU AU2017278099A patent/AU2017278099B2/en active Active
- 2017-06-02 JP JP2018564979A patent/JP7058610B2/ja active Active
- 2017-06-02 SG SG11201810765PA patent/SG11201810765PA/en unknown
- 2017-06-02 EP EP17810768.6A patent/EP3465335A4/en active Pending
- 2017-06-02 WO PCT/US2017/035826 patent/WO2017213999A1/en not_active Ceased
- 2017-06-02 KR KR1020197000530A patent/KR102519244B1/ko active Active
-
2018
- 2018-12-06 IL IL263561A patent/IL263561B/en unknown
- 2018-12-26 CO CONC2018/0014167A patent/CO2018014167A2/es unknown
-
2019
- 2019-07-29 US US16/525,437 patent/US10562839B2/en active Active
- 2019-07-31 US US16/528,524 patent/US10647658B2/en active Active
-
2020
- 2020-12-02 US US17/110,236 patent/US11608308B2/en active Active
-
2021
- 2021-06-07 AU AU2021203726A patent/AU2021203726C1/en active Active
- 2021-10-26 JP JP2021174538A patent/JP7479337B2/ja active Active
-
2022
- 2022-03-24 IL IL291694A patent/IL291694A/en unknown
-
2023
- 2023-12-21 JP JP2023215845A patent/JP2024028287A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201810765PA (en) | Medium chain fatty acid esters of beta-hydroxybutyrate and butanediol and compositions and methods for using same | |
| SG11201903697WA (en) | Liver organoid compositions and methods of making and using same | |
| SG11201805645QA (en) | Lsd1 inhibitors | |
| SG11201906891RA (en) | Methods for the administration of certain vmat2 inhibitors | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201408769QA (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
| SG11201901658PA (en) | Beta-lactamase inhibitor compounds | |
| SG11201806583XA (en) | Compositions containing tucaresol or its analogs | |
| SG11201811237WA (en) | Combination therapies | |
| SG11201908786VA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201808337TA (en) | Deactivation wipe kit and method of forming and using the same | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
| SG11201809875VA (en) | Compositions and methods for treating spinal muscular atrophy | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900123TA (en) | Compositions and methods for treating frontotemporal dementia | |
| SG11201804721SA (en) | Modulators of complement activity | |
| SG11201909064RA (en) | Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer | |
| SG11201901070YA (en) | Formulations for oral administration of active agents | |
| SG11201811686UA (en) | 18f-labeled triazole containing psma inhibitors | |
| SG11201806133UA (en) | Intermediates in the synthesis of eribulin and related methods of synthesis | |
| SG11201408171SA (en) | Fbxo3 inhibitors |